

## NPI Summary Submission Report by Measure Final 2008 Physician Quality Reporting Initiative

Report Date: 09/24/2010

This summary is provided to assist eligible professionals and their staff in interpreting the NPI Summary Submission Report by Measure. This report outlines the number of NPIs who are eligible to report the measures, are actually reporting the measures, and have satisfactorily reported the measures.

This report has been updated to account for the revised metrics as a result of all 2008 supplemental payments.

### Column Definitions:

- Reporting Denominator: Eligible Cases - The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.
- Numerator: Valid QDCs Reported - For each measure, the # of instances where a TIN/NPI combination submitted a valid QDC for that measure.
- National Reporting Rate - The # of reported instances divided by the eligible cases.
- # Eligible NPI - The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.
  
- # NPI Submitting - The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.
- % Total Eligible NPI Submitting - The # of TIN/NPI submitting divided by the # of NPI eligible.
- # NPI Submitting ≥80% - The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.
- % Submitting ≥80% - The # of TIN/NPI submitting ≥80% divided by the # of NPI submitting.

### How to Read the NPI Summary Submission Report by Measure:

Using Measure #47-Advance Care Plan as an example, we find the following information as we read across each column:

The first three columns after the measure title summarized the overall participant reporting information. 880,190 denominator eligible cases were in claims for this measure. 394,154 of which were reported with a quality-data code (QDC) for the measure. Therefore, the national reporting rate for all TIN/NPIs reporting this measure is 44.78%. 598,813 NPIs could have reported on this measure based on claims that were denominator eligible. Of those NPIs, 4,271 (0.71%) NPIs actually submitted a QDC for the measure. 1,109 (25.97%) of the NPIs submitting a QDC for the measure had a reporting rate of 80% or above.

### Analysis Findings Include:

1. Measure #124 HIT - Adoption/Use of EHRs and #128 Universal Weight Screening and Follow-Up had the greatest number of eligible providers (734,927 and 732,233, respectively).
2. Measure #54 ECG Performed for Non-Traumatic Chest Pain and #57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia had the highest number of NPIs submitting, with 33,874 and 32,306 NPIs submitting, respectively.
3. There were several measures where the submission rate of eligible providers was less than 1%. The lowest submission rates for measures with eligible providers were on measures #129 Universal Vaccine Screening and Counseling (0.06%) and #116 Inappropriate Antibiotic Treatment for Adults (0.07%).
4. 100% of eligible NPIs submitted QDCs for measures #106 Patients who have MD Disorder who meet DSM IV Criteria and #107 Patients who have MD Disorder who are Assessed for Suicide Risks. The high participation rate on this measure is due to the measure specifications.
5. Of submitting NPIs, the measures with the greatest proportion of NPIs submitting at or above 80% were: #106 Patients who have MD Disorder who meet DSM IV Criteria (100%) and #30 Timing of Prophylactic Antibiotics - Administering Physician (94.54%).

NPI Summary Submission Report by Measure  
 Report Includes Data from the January 2008 through February 2009 TAP File

Clinical Condition and Measure	Participant Reporting Information			NPI Participation per Measure			# NPI Submitting	% Total Eligible NPI Submitting <sup>f</sup>	# NPI Submitting ≥80% <sup>g</sup>	% Submitting ≥80% <sup>h</sup>
	Reporting Denominator: Eligible Cases <sup>a</sup>	Numerator: Valid QDCs Reported <sup>b</sup>	National Reporting Rate <sup>c</sup>	# Eligible NPI <sup>d</sup>	# NPI Submitting <sup>e</sup>	% Total Eligible NPI Submitting <sup>f</sup>				
Advance Care Plan <sup>1</sup>				598,813	4,271	0.71%	1,109		25.97%	
#47 Advance Care Plan	880,190	394,154	44.78%	598,813	4,271	0.71%	1,109		25.97%	
Arthritis-Osteoarthritis <sup>1</sup>				208,987	350	0.17%	84		24.00%	
#109 Patients with OA with an Assessment of Pain and Function	67,859	32,639	48.10%	208,987	350	0.17%	84		24.00%	
Arthritis-Rheumatoid <sup>1</sup>				140,301	387	0.28%	167		43.15%	
#108 DMARD Therapy in Rheumatoid Arthritis	28,083	17,682	62.96%	140,301	387	0.28%	167		43.15%	
Asthma <sup>1</sup>				45,928	314	0.68%	96		30.57%	
#53 Pharmacologic Therapy	588	415	70.58%	45,928	297	0.65%	207		69.70%	
#64 Asthma Assessment	363	253	69.70%	45,928	168	0.37%	112		66.67%	
Breast Cancer <sup>1</sup>				512,270	8,294	1.62%	2,267		27.33%	
#71 Hormonal Therapy for Stage IC-III ER/PR Positive	100,590	50,018	49.72%	101,351	1,535	1.51%	364		23.71%	
#74 RT Recommended for Invasive Breast Cancer Patients with Breast Conserving Surgery	5,070	2,522	49.74%	20,645	731	3.54%	216		29.55%	
#99 Breast Cancer Patients with a pT and pN Category and Histologic Grade	43,028	30,086	69.92%	7,491	4,072	54.36%	2,022		49.66%	
#112 Screening Mammography	124,110	37,734	30.40%	504,373	2,224	0.44%	288		12.95%	
Bronchitis <sup>1</sup>				98,549	66	0.07%	25		37.88%	
#116 Inappropriate Antibiotic Treatment for Adults	338	149	44.08%	98,549	66	0.07%	25		37.88%	
Coronary Artery Bypass Graft (CABG) <sup>1</sup>				4,093	1,279	31.25%	511		39.95%	
#43 Use of IMA in CABG Surgery	37,497	28,357	75.62%	4,093	1,273	31.10%	800		62.84%	
#44 Preoperative Beta-blocker in Patients with Isolated CABG Surgery	27,007	18,988	70.31%	4,093	912	22.28%	508		55.70%	
CAD <sup>1</sup>				239,573	12,403	5.18%	832		6.71%	
#118 ACE or ARB Therapy for Patients with CAD and Diabetes and/or LVSD	149,091	41,754	28.01%	215,698	934	0.43%	142		15.20%	
#6 Oral Antiplatelet Therapy Prescribed for Patients with CAD	1,434,257	1,011,651	70.53%	239,573	12,242	5.11%	5,925		48.40%	
#7 Beta-blocker Therapy for CAD Patients with Prior MI	161,526	123,161	76.25%	97,951	5,870	5.99%	3,066		52.23%	
Chemotherapy <sup>1</sup>				6,870	946	13.77%	243		25.69%	
#73 Plan Documented Before Chemotherapy Administered	15,571	8,215	52.76%	6,870	946	13.77%	243		25.69%	
Chest Pain <sup>1</sup>				64,069	33,874	52.87%	24,156		71.31%	
#54 ECG Performed for Non-Traumatic Chest Pain	1,161,992	918,168	79.02%	64,069	33,874	52.87%	24,156		71.31%	
Chronic Kidney Disease (CKD) <sup>1</sup>				37,448	480	1.28%	53		11.04%	
#120 ACE Inhibitor or ARB Therapy in Patients with CKD	1,193	766	64.21%	3,594	109	3.03%	61		55.96%	
#121 Laboratory Testing (Calcium, Phosphorus, iPTH and Lipid Profile)	9,782	4,565	46.67%	37,448	205	0.55%	42		20.49%	
#122 Blood Pressure Management	42,076	23,263	55.29%	37,448	400	1.07%	152		38.00%	
#123 Plan of Care: Elevated Hemoglobin for Patients Receiving ESAs	24,187	12,666	52.37%	37,448	299	0.80%	89		29.77%	
Colon Cancer <sup>1</sup>				67,392	1,216	1.80%	281		23.11%	
#72 Chemotherapy for Stage III	26,060	13,044	50.05%	67,392	1,216	1.80%	281		23.11%	
Colorectal Cancer (CRC) <sup>1</sup>				559,033	6,344	1.13%	2,718		42.84%	
#100 CRC Patients with a pT and pN Category and Histologic Grade	25,737	20,039	77.86%	7,117	3,892	54.69%	2,447		62.87%	
#113 CRC Screening	494,773	129,879	26.25%	552,058	2,452	0.44%	305		12.44%	
Chronic Obstructive Pulmonary Disease (COPD) <sup>1</sup>				207,101	1,969	0.95%	399		20.26%	
#51 Spirometry Evaluation	131,598	76,467	58.11%	207,101	1,738	0.84%	644		37.05%	
#52 Bronchodilator Therapy	118,571	68,359	57.65%	207,101	1,441	0.70%	458		31.78%	

<sup>a</sup> The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.  
<sup>b</sup> For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.  
<sup>c</sup> The # of reported instances divided by the eligible cases.  
<sup>d</sup> The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.  
<sup>e</sup> The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.  
<sup>f</sup> The # of TIN/NPI submitting divided by the # of NPI eligible.  
<sup>g</sup> The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.  
<sup>h</sup> The # of TIN/NPI submitting ≥80% divided by the # of NPI submitting.  
<sup>i</sup> Unduplicated counts of NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.  
 Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Clinical Condition and Measure	Participant Reporting Information			# Eligible NPI <sup>d</sup>	NPI Participation per Measure		# NPI Submitting $\geq 80\%$ <sup>g</sup>	% Submitting $\geq 80\%$ <sup>h</sup>
	Reporting Denominator: Eligible Cases <sup>a</sup>	Numerator: Valid QDCs Reported <sup>b</sup>	National Reporting Rate <sup>c</sup>		# NPI Submitting <sup>e</sup>	% Total Eligible NPI Submitting <sup>f</sup>		
Chronic Obstructive Pulmonary Disease (COPD) <sup>i</sup>				207,101	1,969	0.95%	399	20.26%
#51 Spirometry Evaluation	131,598	76,467	58.11%	207,101	1,738	0.84%	644	37.05%
#52 Bronchodilator Therapy	118,571	68,359	57.65%	207,101	1,441	0.70%	458	31.78%
Catheter-Related Bloodstream Infections (CRBSI) <sup>i</sup>				87,905	4,326	4.92%	1,591	36.78%
#76 Prevention of CRBSI - Central Venous Catheter Insertion Protocol	92,670	54,379	58.68%	87,905	4,326	4.92%	1,591	36.78%
Depression <sup>i</sup>				238,352	747	0.31%	222	29.72%
#9 Antidepressant Meds During Acute Phase for Patients with New Episode of MD	17,295	8,903	51.48%	238,352	603	0.25%	210	34.83%
#106 Patients who have MD Disorder who meet DSM IV Criteria	3,548	3,548	100.00%	99	99	100.00%	99	100.00%
#107 Patients who have MD Disorder who are Assessed for Suicide Risks	10,074	8,227	81.67%	196	196	100.00%	120	61.22%
Diabetes <sup>i</sup>				354,074	28,221	7.97%	91	0.32%
#1 Hemoglobin A1c Poor Control	639,507	380,902	59.56%	295,736	18,200	6.15%	7,895	43.38%
#2 Low Density Lipoprotein Control	607,915	358,323	58.94%	295,736	17,479	5.91%	7,463	42.70%
#3 High Blood Pressure Control	619,615	370,567	59.81%	295,736	17,411	5.89%	7,605	43.68%
#18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	353,895	218,587	61.77%	43,463	7,132	16.41%	2,437	34.17%
#19 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	275,327	151,811	55.14%	43,463	5,674	13.05%	1,789	31.53%
#117 Dilated Eye Exam in Diabetic Patient	426,037	217,447	51.04%	320,285	6,606	2.06%	1,489	22.54%
#119 Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	90,791	33,372	36.76%	320,880	2,136	0.67%	273	12.78%
Diabetes <sup>i</sup>				354,074	28,221	7.97%	91	0.32%
#126 Diabetic Foot and Ankle Care, Peripheral Neuropathy: Neurological Evaluation	68,021	26,854	39.48%	317,143	924	0.29%	121	13.10%
#127 Diabetic Foot and Ankle Care, Ulcer Prevention: Evaluation of Footwear	25,686	9,967	38.80%	317,143	348	0.11%	53	15.23%
End Stage Renal Disease (ESRD)				9,004	837	9.30%	100	11.95%
#78 Vascular Access for Patients Undergoing Hemodialysis	69,982	29,680	42.41%	8,889	495	5.57%	106	21.41%
#79 Influenza Vaccination in Patients with ESRD	75,496	27,010	35.78%	9,004	453	5.03%	58	12.80%
#80 Plan of Care for ESRD Patients with Anemia	295,810	188,510	63.73%	9,004	660	7.33%	236	35.76%
#81 Plan of Care for Inadequate Hemodialysis	264,032	159,772	60.51%	8,889	627	7.05%	211	33.65%
#82 Plan of Care for Inadequate Peritoneal Dialysis	10,998	5,704	51.86%	6,666	421	6.32%	120	28.50%
Falls <sup>i</sup>				578,391	8,702	1.50%	3,045	34.99%
#4 Screening for Future Fall Risk	1,050,888	479,336	45.61%	578,391	8,702	1.50%	3,045	34.99%
GERD <sup>i</sup>				200,667	754	0.38%	225	29.84%
#77 Assessment of GERD Symptoms in Patients Receiving Chronic Medication for GERD	36,980	21,382	57.82%	200,667	754	0.38%	225	29.84%
Glaucoma <sup>i</sup>				45,292	8,769	19.36%	3,619	41.27%
#12 Optic Nerve Evaluation	1,187,735	798,566	67.23%	45,292	8,769	19.36%	3,619	41.27%
Heart Failure <sup>i</sup>				229,201	9,481	4.14%	2,792	29.45%
#5 ACE Inhibitor or ARB Therapy for LVSD	347,469	211,582	60.89%	229,201	9,256	4.04%	3,594	38.83%
#8 Beta-blocker Therapy for LVSD	208,806	131,953	63.19%	203,591	4,660	2.29%	2,137	45.86%
Hepatitis C (HCV)				62,791	429	0.68%	14	3.26%
#83 Testing of Patients with Chronic HCV for Hepatitis C Viremia	2,573	1,390	54.02%	62,791	251	0.40%	83	33.07%
#84 Initial Hepatitis C RNA Testing	2,118	1,481	69.92%	32,723	208	0.64%	97	46.63%
#85 Genotype Testing Prior to Therapy	2,726	1,730	63.46%	32,723	218	0.67%	93	42.66%
#86 Consideration for Antiviral Therapy	1,927	1,183	61.39%	32,723	162	0.50%	54	33.33%
#87 RNA Testing at Week 12 of Therapy	981	441	44.95%	32,723	97	0.30%	28	28.87%
#88 Hepatitis A and B Vaccination	2,009	1,089	54.21%	62,791	209	0.33%	78	37.32%
#89 Counseling Patients Regarding Use of Alcohol	1,477	705	47.73%	62,791	171	0.27%	53	30.99%
#90 Counseling Patients Regarding Use of Contraception Prior to Starting Antiviral Therapy	275	157	57.09%	23,738	40	0.17%	15	37.50%

<sup>a</sup> The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.  
<sup>b</sup> For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.  
<sup>c</sup> The # of reported instances divided by the eligible cases.  
<sup>d</sup> The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.  
<sup>e</sup> The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.  
<sup>f</sup> The # of TIN/NPI submitting divided by the # of NPI eligible.  
<sup>g</sup> The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.  
<sup>h</sup> The # of TIN/NPI submitting  $\geq 80\%$  divided by the # of NPI submitting.  
<sup>i</sup> Unduplicated counts of NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.  
Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDJ).

Clinical Condition and Measure	Participant Reporting Information			# Eligible NPI <sup>d</sup>	NPI Participation per Measure		# NPI Submitting ≥80% <sup>g</sup>	% Submitting ≥80% <sup>h</sup>
	Reporting Denominator: Eligible Cases <sup>a</sup>	Numerator: Valid QDCs Reported <sup>b</sup>	National Reporting Rate <sup>c</sup>		# NPI Submitting <sup>f</sup>	% Total Eligible NPI Submitting <sup>f</sup>		
HIT				734,927	11,077	1.51%	350	3.16%
#124 HIT - Adoption/Use of EHRs	4,848,967	2,284,720	47.12%	734,927	8,792	1.20%	2,772	31.53%
#125 HIT - Adoption/Use of e-Prescribing	3,436,751	414,783	12.07%	646,312	3,867	0.60%	241	6.23%
Imaging-Stroke				53,277	8,005	15.03%	2,388	29.83%
#10 CT or MRI Reports	381,822	219,202	57.41%	34,261	7,360	21.48%	2,304	31.30%
#11 Carotid Imaging Reports	88,560	55,322	62.47%	41,999	5,345	12.73%	2,102	39.33%
Influenza <sup>i</sup>				621,735	3,234	0.52%	9	0.28%
#110 Vaccination for Patients ≥ 50 Years Old	758,174	181,859	23.99%	543,342	3,114	0.57%	212	6.81%
#129 Universal Vaccine Screening and Counseling	121,418	38,336	31.57%	602,616	338	0.06%	27	7.99%
Leukemia (CLL) <sup>i</sup>				32,689	1,397	4.27%	568	40.66%
#70 Baseline Flow Cytometry	16,935	10,683	63.08%	32,689	1,397	4.27%	568	40.66%
Macular Degeneration <sup>i</sup>				68,304	8,777	12.85%	3,216	36.64%
#14 Dilated Macular Examination	1,026,261	673,110	65.59%	68,304	8,777	12.85%	3,216	36.64%
Myelodysplastic Syndrome (MDS) and Acute Leukemias <sup>i</sup>				24,662	1,279	5.19%	176	13.76%
#67 Baseline Cytogenetic Testing Performed on Bone Marrow	19,237	11,022	57.30%	24,662	1,037	4.20%	298	28.74%
#68 Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	16,754	9,011	53.78%	19,621	877	4.47%	228	26.00%
Medication Management <sup>i</sup>				623,181	3,632	0.58%	768	21.15%
#46 Medication Reconciliation	71,319	22,431	31.45%	428,887	1,966	0.46%	369	18.77%
#130 Documentation of Current Medications	98,852	45,616	46.15%	265,799	1,681	0.63%	461	27.42%
Mental Health <sup>i</sup>				97,081	328	0.34%	34	10.37%
#133 Screening for Cognitive Impairment	11,016	7,718	70.06%	58,941	265	0.47%	156	58.87%
#134 Screening for Clinical Depression	9,159	4,374	47.76%	98,874	151	0.16%	39	25.83%
Myeloma <sup>i</sup>				31,967	1,544	4.83%	592	38.34%
#69 Treatment with Bisphosphonates	13,667	8,087	59.17%	31,967	1,544	4.83%	592	38.34%
Myocardial Infarction <sup>i</sup>				30,087	13,496	44.86%	10,067	74.59%
#28 Aspirin at Arrival	55,841	44,774	80.18%	30,087	13,496	44.86%	10,067	74.59%
Obesity <sup>i</sup>				732,233	1,686	0.23%	277	16.43%
#128 Universal Weight Screening and Follow-Up	385,551	85,527	22.18%	732,233	1,686	0.23%	277	16.43%
Osteoporosis <sup>i</sup>				520,890	6,888	1.32%	800	11.61%
#24 Communication with the Physician Managing Ongoing Care Post-Fracture	18,988	7,426	39.11%	112,006	784	0.70%	200	25.51%
#39 Screening or Therapy for Women Aged 65 Years and Older	534,383	210,429	39.38%	509,302	4,133	0.81%	1,034	25.02%
#40 Management Following Fracture	14,908	5,026	33.71%	112,006	1,090	0.97%	354	32.48%
#41 Pharmacologic Therapy	120,831	62,030	51.34%	179,172	3,261	1.82%	1,000	30.67%
Otitis <sup>i</sup>				85,396	156	0.18%	17	10.90%
#91 AOE: Topical Therapy	2,841	1,405	49.45%	85,377	144	0.17%	57	39.58%
#92 AOE: Pain Assessment	3,230	1,538	47.62%	85,377	99	0.12%	24	24.24%
#93 AOE: Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	2,777	1,284	46.24%	85,377	130	0.15%	43	33.08%
#94 OME: Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility	0	0	0.00%	27	0	0.00%	0	0.00%
#95 OME: Hearing Testing	0	0	0.00%	16	0	0.00%	0	0.00%
#96 OME: Antihistamines or Decongestants – Avoidance of Inappropriate Use	0	0	0.00%	27	0	0.00%	0	0.00%
#97 OME: Systemic Antimicrobials – Avoidance of Inappropriate Use	0	0	0.00%	27	0	0.00%	0	0.00%
#98 OME: Systemic Corticosteroids – Avoidance of Inappropriate Use	0	0	0.00%	27	0	0.00%	0	0.00%
Pain Management <sup>i</sup>				164,130	3,525	2.15%	1,442	40.91%
#131 Assessment Prior to Initiation of Patient Treatment	357,720	116,018	32.43%	164,130	3,525	2.15%	1,442	40.91%
Perioperative <sup>i</sup>				137,732	29,944	21.74%	22,222	74.21%
#20 Timing of Antibiotic Prophylaxis - Ordering Physician	368,445	237,446	64.45%	101,802	7,079	6.95%	3,175	44.85%

<sup>a</sup> The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.

<sup>b</sup> For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

<sup>c</sup> The # of reported instances divided by the eligible cases.

<sup>d</sup> The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

<sup>e</sup> The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

<sup>f</sup> The # of TIN/NPI submitting divided by the # of NPI eligible.

<sup>g</sup> The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

<sup>h</sup> The # of TIN/NPI submitting ≥80% divided by the # of NPI submitting.

<sup>i</sup> Unduplicated counts of NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCM and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Clinical Condition and Measure	Participant Reporting Information			# Eligible NPI <sup>d</sup>	NPI Participation per Measure		# NPI Submitting $\geq 80\%$ <sup>g</sup>	% Submitting $\geq 80\%$ <sup>h</sup>
	Reporting Denominator: Eligible Cases <sup>a</sup>	Numerator: Valid QDCs Reported <sup>b</sup>	National Reporting Rate <sup>c</sup>		# NPI Submitting <sup>f</sup>	% Total Eligible NPI Submitting <sup>f</sup>		
Perioperative <sup>e</sup>				137,732	29,944	21.74%	22,222	74.21%
#21 Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	281,881	176,378	62.57%	90,879	5,339	5.87%	2,322	43.49%
#22 Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	217,608	133,092	61.16%	94,008	4,982	5.30%	2,143	43.01%
#23 VTE Prophylaxis	173,573	109,588	63.14%	78,072	4,238	5.43%	1,961	46.27%
#30 Timing of Prophylactic Antibiotics - Administering Physician	1,417,915	1,371,470	96.72%	29,426	24,051	81.73%	22,739	94.54%
#45 Discontinuation of Prophylactic Antibiotics	120,914	81,450	67.36%	4,872	1,123	23.05%	600	53.43%
Pharyngitis <sup>e</sup>				135	0	0.00%		
#66 Appropriate Testing for Children	0	0	0.00%	135	0	0.00%	0	0.00%
Plan of Care <sup>e</sup>				142,859	3,228	2.26%	1,216	37.67%
#132 Patient Co-Development of Treatment Plan	151,450	94,693	62.52%	142,859	3,228	2.26%	1,216	37.67%
Pneumonia <sup>e</sup>				239,665	34,453	14.38%	13,403	38.90%
#56 Vital Signs for Community-Acquired Bacterial Pneumonia	496,490	399,954	80.56%	197,515	28,354	14.36%	20,638	72.79%
#57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia	542,520	455,998	84.05%	197,515	32,306	16.36%	25,358	78.49%
#58 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia	474,024	387,413	81.73%	197,515	28,253	14.30%	21,595	76.43%
#59 Empiric Antibiotic for Community-Acquired Bacterial Pneumonia	334,926	262,203	78.29%	197,515	19,697	9.97%	14,227	72.23%
#75 Prevention of Ventilator-Associated Pneumonia - Pneumonia Pneumococcal <sup>e</sup>	7,392	3,708	50.16%	74,929	112	0.15%	35	31.25%
#111 Vaccination for Patients 65 years and Older	805,329	250,489	31.10%	555,681	3,490	0.63%	516	14.79%
Prostate Cancer <sup>e</sup>				8,813	687	7.80%	57	8.30%
#101 Appropriate Initial Evaluation of Patients with Prostate Cancer	8,117	4,301	52.99%	8,723	435	4.99%	135	31.03%
#102 Inappropriate Use of Bone Scan for Staging Low-Risk Prostate Cancer Patients	36,121	18,537	51.32%	8,723	221	2.53%	73	33.03%
#103 Review of Treatment Options in Patients with Clinically Localized Prostate Cancer	6,852	3,188	46.53%	7,710	373	4.84%	109	29.22%
#104 Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	4,154	1,762	42.42%	4,442	193	4.34%	25	12.95%
#105 Three-dimensional Radiotherapy for Patients with Prostate Cancer	100,439	59,476	59.22%	4,372	427	9.77%	133	31.15%
Stroke and Stroke Rehabilitation <sup>e</sup>				122,776	3,503	2.85%	298	8.51%
#31 DVT Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	13,266	7,185	54.16%	90,977	1,067	1.17%	430	40.30%
#32 Discharged on Antiplatelet Therapy	25,291	13,832	54.69%	90,883	2,321	2.55%	930	40.07%
#33 Anticoagulant Therapy Prescribed for Afib at Discharge	1,614	1,059	65.61%	23,952	590	2.46%	339	57.46%
#34 t-PA Considered	10,348	6,023	58.20%	78,877	1,152	1.46%	680	59.03%
#35 Screening for Dysphagia	10,248	5,550	54.16%	70,549	772	1.09%	292	37.82%
#36 Consideration of Rehabilitation Services	14,053	7,460	53.08%	67,680	1,331	1.97%	540	40.57%
Syncope <sup>e</sup>				50,506	28,488	56.41%	21,630	75.93%
#55 ECG Performed for Syncope	345,947	284,734	82.31%	50,506	28,488	56.41%	21,630	75.93%
Tobacco Use <sup>e</sup>				568,003	6,099	1.07%	519	8.51%
#114 Inquiry Regarding Tobacco Use	1,333,374	522,767	39.21%	539,000	5,567	1.03%	1,275	22.90%
#115 Advising Smokers to Quit	1,115,694	332,123	29.77%	568,003	4,149	0.73%	513	12.36%
Upper Respiratory Infection (URI) <sup>e</sup>				176	0	0.00%		
#65 Appropriate Treatment for Children	0	0	0.00%	176	0	0.00%	0	0.00%
Urinary Incontinence (UI) <sup>e</sup>				509,499	3,545	0.70%	481	13.57%
#48 Assessment of Presence or Absence of UI in Women Aged 65 Years and Older	398,964	125,373	31.42%	509,302	3,299	0.65%	577	17.49%
#49 Characterization of UI in Women Aged 65 Years and Older	55,410	32,217	58.14%	119,384	1,446	1.21%	453	31.33%
#50 Plan of Care for UI in Women Aged 65 Years and Older	52,531	31,001	59.01%	119,384	1,389	1.16%	465	33.48%
<b>National Total<sup>f</sup></b>				<b>963,835</b>	<b>144,972</b>	<b>15.04%</b>	<b>95,855</b>	<b>66.12%</b>

<sup>a</sup> The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.  
<sup>b</sup> For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.  
<sup>c</sup> The # of reported instances divided by the eligible cases.  
<sup>d</sup> The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.  
<sup>e</sup> The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.  
<sup>f</sup> The # of TIN/NPI submitting divided by the # of NPI eligible.  
<sup>g</sup> The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.  
<sup>h</sup> The # of TIN/NPI submitting  $\geq 80\%$  divided by the # of NPI submitting.  
<sup>i</sup> Unduplicated counts of NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.  
Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDJ).